Thematic Research And Development Areas

Oncology Genomics

The prevention, early diagnosis and treatment of cancer otherwise known as oncology is an important branch of medicine. Alteration in genomic DNA is frequently associated with the initiation and development of cancers. Advances in genomic technologies has made it possible to probe the DNA, the transcribed product (mRNA) and Protein.

Our aim at the CGNPH is to use cutting edge technologies to interrogate the genome of various cancer cells to identify unique omics signatures that could easily identify individual risk to the development of cancer, provide a means of less invasive diagnostic alternative to tissue removal and identify specific target for precision oncology

Genomics of Diabetes and Metabolic Syndrome

Metabolic syndrome is a multifactorial disease condition defined by a clustering of risk factors including hypertension, insulin resistance and obesity. This clustering of risk factors predisposes an individual to an increased risk for diabetes and cardiovascular disease.

Genomic studies ae beginning to show a number of overlapping genes and polymorphisms that influence both the development of diabetes and Metabolic syndrome.

At CGNPH, we are committed to providing genomic research data that will help revolutionize the screening, diagnosis and management of metabolic syndrome and diabetes with a view to ensuring personalized (tailored) health care to individual's need.


Pharmacogenomics studies variations in the genetic make-up of an individual and relates this to drug response. The benefits of minimizing the risk of toxicity and increasing effectiveness are the key drivers of personalized medicine.

At CGNPH, we aim to understand germline genetic variations that are present within our community by adopting a candidae gene approach and thereby address the lack of pharmacogenomic data as regards the therapy of non-communicable diseases.

Mental Health

Mental health is concerned with the overall emotional, psychological and social wellbeing. This affects how we think, feel, act and determine how we hadnle stress, relate to others and make choices.
At CGNPH, we re committed to providing information, data and resources that may improve and speed the understanding of disease etiology, refinement of diagnostic systems and development of novel therapeutic agents and personalized care that will enhance provision of quality healthcare.

Cardiovascular, Hypertension and Stroke

At CGNPH, we seek to stimulate innovative and impactful research that explores novel biomarkers and genomic variants associated with the development and progression of cardiovascular and cardiometabolic diseases across the lifespan in cohorts with chronic diseases; and to explore markers for risk prediction and stratification, disease diagnosis and prognostication and personalized treatment. Also of research interest is the role of micronutrients in the aetiiogenesis and modulation of cardiovascular and cardiometabolic diseases across the lifespan.

The fetal origins hypothesis of CVDs and the impact of intrauterine growth on developmental adaptations that program vulnerability to cardiovascular and cardiometabolic diseases later in life constitute an important part of our program.

Point-of-Care Testing and Medical Devices

Point-of-Care Testing (POCT) is essential for the rapid detection of analytes near to the patient, which facilitates better disease diagnosis, monitoring, and management. At CGNPH, our R&D applies artificial intelligence, Big Data and Machine Learning Techniques to provide better and personalized healthcare.

We focus on developing from innovation through to commercialization, effective and affordable in-vitro POCT devices targeted at NCDs for low-income economies especially in Africa. We co-innovate with industrial partners to deliver better healthcare products and services.

NCDs-CDs interface

The combine effect of non-communicable (NCDs) and communicable diseases is contributing enormously to the shorter life span experienced globally by individual with such comorbidity.

The fatality in people with hypertension and type 2 diabetes mellitus is increasing with infectious diseases like HIV and Tuberculosis. Covid-19 pandemic has proved this hypothesis to be true because most fatality during the 2019-2021 pandemic are among individuals with such comorbidity.

This non-communicable and communicable interphase thematic group is designed to bridge the gap using genomics and molecular biology technology to study the impact of combine effect of non-communicable and communicable disease, in order to provide mitigation and drug target for evidence base patients care management.